Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy
about
HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillanceNatural selection of tumor variants in the generation of "tumor escape" phenotypesThe Medicinal Mushroom Agaricus blazei Murrill: Review of Literature and Pharmaco-Toxicological ProblemsDengue Virus Replicon Expressing the Nonstructural Proteins Suffices To Enhance Membrane Expression of HLA Class I and Inhibit Lysis by Human NK CellsSusceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantationImmunotherapy in acute leukemiaHeterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma.Canine transmissible venereal tumour: cytogenetic origin, immunophenotype, and immunobiology. A review.KIR3DL01 recognition of Bw4 ligands in the rhesus macaque: maintenance of Bw4 specificity since the divergence of apes and Old World monkeysT-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.Combinations of immunotherapy and radiation in cancer therapy.Assumptions of the tumor 'escape' hypothesis.Cancer vaccines: progress reveals new complexities.Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time.Challenges and future perspectives of T cell immunotherapy in cancerDeveloping recombinant and synthetic vaccines for the treatment of melanoma.HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisitionBiosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules.Potential therapeutic role of natural killer cells in cancer.Engineering antigen-specific primary human NK cells against HER-2 positive carcinomasSurvival in acute myeloid leukemia is associated with NKp44 splice variants.Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.The killer-cell immunoglobulin-like receptors of macaques.Natural killer cells in inflammatory heart disease.Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.Immune and molecular correlates in melanoma treated with immune checkpoint blockade.Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT.Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles.Resistance to checkpoint blockade therapy through inactivation of antigen presentation.CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination.Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack.Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy.Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints.Genomic mechanisms of immune evasion in colorectal cancer: from discovery to clinical practice
P2860
Q24323589-386493F7-12F8-4D14-A965-F94C79F32EE8Q24551158-CEAE77F5-F5A5-470C-ADB0-D9526B6F341FQ24644957-23AE11BD-B13F-44FC-879C-21D453D7F545Q27486580-58F69DC2-A535-4ECE-9D88-53E40D4C2695Q30975364-9DC09939-4AC7-42E8-8729-7D04E8CDFED6Q33564445-AD276D13-25D2-45C8-96FB-3142CBE74D41Q33731552-788DBA29-9E1D-4ACC-B114-397FF6659E8BQ33827463-56455ADF-0BDF-48BD-BE68-812635048171Q33973063-C819C1D8-9826-4A08-9DB8-23E53F4EF506Q34172209-D266B1C8-62B0-4140-A34A-C0B48EA71F0AQ34452013-1ED6841A-6CFF-4BBF-99EA-A078855052B2Q34582640-A70BE3F1-32CB-4664-970D-E02EAD5C3C2CQ34583258-714A59C5-8FED-4C5D-997E-9983D488F384Q34774541-CFF7419C-A704-42CB-AFD5-E19B10B9057DQ35703570-48817C85-AE96-4D21-B544-125E39F2FC29Q35843507-303298CD-B1FC-417F-A682-E32CDB610765Q35946196-4AB6A7A0-27D9-400E-BD9B-823846D11BC4Q36184954-F5A8E66E-0873-4F73-B802-99067D2DF498Q36617745-D811C1F1-3DD1-4A08-B34B-F945F8EE141DQ36675436-84F824C5-A1AC-43FC-9170-6344B4457457Q36970863-C360CA6B-237B-4BA1-9E74-E94740CD2040Q37362807-35F6BF6D-E925-4D15-BBD9-15203700FAC2Q37372822-7DB828BB-3ABF-4C52-9909-00423B58B67EQ38074885-58301085-3516-4A76-A87E-EFE5D09FD027Q38568886-0DF9A8F1-D355-4A02-8C2A-16F19ADDA75FQ39022829-AF84698E-6DB0-4049-AE91-089EF72C42DAQ39312652-A49879C2-EBA5-48A6-8F9E-B440E08EAF30Q39329603-130D1F71-38AC-4A5E-ACBA-FD8C095D4FA8Q40712474-4ED8ACAE-D579-40BD-B7F2-63520D76E303Q40741032-AE951E9B-2FE1-406D-B64B-17FF9D4C4702Q40975346-2E60213D-2E5C-44A2-AF44-AC983E568239Q41013301-96D1333D-E37E-4238-91CA-3B902B5ABCB4Q42630391-CEE4178B-E7E1-4EBD-BAF9-B8A845CEB58FQ45864088-7C2FFCF9-830D-4097-8FFB-11762C2D7962Q47632531-DC869BD0-0188-4539-9869-8984BBB2976DQ47785375-0662ADFE-91F6-4E1B-9454-CD783E675C78Q49630355-6751FAEC-19D2-46E9-9141-873498A643B1Q58554079-1D3F358B-2F03-43FD-8427-5B5414036397
P2860
Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Natural killer cell lines kill ...... tions for cancer immunotherapy
@ast
Natural killer cell lines kill ...... tions for cancer immunotherapy
@en
type
label
Natural killer cell lines kill ...... tions for cancer immunotherapy
@ast
Natural killer cell lines kill ...... tions for cancer immunotherapy
@en
prefLabel
Natural killer cell lines kill ...... tions for cancer immunotherapy
@ast
Natural killer cell lines kill ...... tions for cancer immunotherapy
@en
P2093
P2860
P356
P1476
Natural killer cell lines kill ...... tions for cancer immunotherapy
@en
P2093
A Porgador
N P Restifo
O Mandelboim
P2860
P304
13140-13145
P356
10.1073/PNAS.94.24.13140
P407
P577
1997-11-01T00:00:00Z